Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of human coagulation factor XIIIa assessed as maximal inhibition of factor 13a mediated fibrin polymerization at 5 to 500 uM incubated for 24 hrs by SDS-PAGE analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human coagulation factor XIIIa assessed as inhibition of factor 13a mediated fibrin polymerization incubated for 24 hrs by SDS-PAGE analysis
Inhibition of human coagulation factor XIIIa assessed as enzyme residual activity at 100 uM in presence of polybrene by Spectrofluorometric assay
Binding affinity to human coagulation factor XIIIa by Spectrofluorometric assay
Inhibition of human coagulation factor XIIIa assessed as maximal efficacy upto 20 nM
Assay data:2 Tested
Inhibition of human recombinant coagulation factor XIIIa
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human coagulation factor XIIIa
Assay data:1 Active, 1 Activity ≤ 1 µM, 3 Tested
Inhibition of human recombinant coagulation factor XIIIa incubated for 55 mins by fluorometric assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of human plasma coagulation factor XIIIa by fluorescence spectrophotometeric assay
Assay data:4 Active, 3 Activity ≤ 1 µM, 4 Tested
Inhibition of human plasma coagulation factor XIIIa
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Binding affinity to human plasma coagulation factor XIIIa assessed as rate constant in presence of GSH by DTNB based UV-fluorescence assay
Assay data:5 Tested
Inhibition of human coagulation factor XIIIa assessed as inhibition of factor 13a mediated crosslinking of fibronectin-collagen incubated for 2 hrs by SDS-PAGE analysis
Reversible inhibition of human factor XIIIa using peptidic FRET-quenched probe A101 as substrate by fluorescence based assay relative to control
Irreversible inhibition of human factor XIIIa using peptidic FRET-quenched probe A101 as substrate assessed as observed binding constant by fluorescence based assay
Assay data:3 Tested
Inhibition of FXIIIa (unknown origin) using peptidic FRET quenched probe A101 as substrate and measured by fluorescence-based assay
Transamidation Assay for Determining Inhibitor Selectivity from US Patent US11472838: "Inhibitors of blood coagulation factor XIII"
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Isopeptidase Assay for Estimating Inhibitor Potency from US Patent US11472838: "Inhibitors of blood coagulation factor XIII"
Assay data:65 Active, 61 Activity ≤ 1 µM, 67 Tested
TG Activity Assays from Article 10.1016/j.chembiol.2015.08.013: "Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions."
Assay data:27 Active, 14 Activity ≤ 1 µM, 29 Tested
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Inactivation of human F13a assessed as rate constant of enzyme inhibition using FRET- quenched A101 as substrate by fluorescence assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on